Higher co-payments increase chance of early discontinuation of breast cancer therapy

A higher prescription co-payment, especially among older women, is associated with both early discontinuation and incomplete use of adjuvant aromatase inhibitor therapy, a life-saving therapy for women with hormone sensitive early stage breast cancer.

Read the whole article on Physorg

More from Physorg